[Clinical trial of drugs for treating urological infections--pipemidic acid].
A method was elaborated for clinical trial of pharmaceuticals for the treatment of infections of kidneys and urinary ducts. The main requirements are as follows: definitive diagnostic criteria for urological infection, monotherapy, systematic control for the drug intake, precisely formulated indices for assessment of the effect, strict follow-up of adverse and toxic effects. The effect was assessed according to a three-stage scale: very good, good and poor, consideration given not only to the clinical and laboratory indices but to adverse effects as well. Pipemidic acid was studied according to that model--the acid being a new chemotherapeutic, similar to nalidixic acid according to chemical composition and action. Out of all 29 patients treated, 19 were with very good effect, with good--6, and with poor--4. The adverse effects were negligible--one patient had light urticarial rash and pruritus.
D000328:Adult; D000368:Aged; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002986:Clinical Trials as Topic / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use*; D010876:Pipemidic Acid / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D009539:Nicotinic Acids; D010876:Pipemidic Acid
Klinichno izpitvane na lekarstveni sredstva za lechenie na uroinfektsii--pipemidinova kiselina.